USP22 and prostate carcinoma: In addition to RM1 prostate cancer, we confirmed that Usp22 inhibition impeded the growth of both orthotopic 4T1 TNBC (Supplemental Figure 3, B and C) and MC38 syngeneic tumors (Supplemental Figure 4, A and B).